

9. LITERATURE LIST

1. Théroux P, Lidon R-M. Unstable angina: pathogenesis, diagnosis and treatment. *Current Problems in Cardiology* 1993;13:159-231
2. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro JH. Insights into the pathogenesis of acute ischemic syndromes. *Circulation* 1988;77:1213-20
3. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. *N Engl J Med* 1992;326:287-91
4. Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Théroux P. New antithrombotics. *Chest* 1995;108(4 Suppl):471S-485S
5. Hirsh J, Weitz JI. New antithrombotic agents. *Lancet* 1999;353:1431-1436
6. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. *Circulation* 1994;90:1522-1536
7. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. *J Clin Invest* 1990;86:385-391
8. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA et al. Aspirin, sulfipyrazone, or both in unstable angina. Results of a Canadian multicenter trial. *N Engl J Med* 1985;313:1369-75
9. Théroux P, Ouimet H, McCans J, Latour J-G, Joly P, Lévy G et al. Aspirin, heparin, or both to treat acute unstable angina. *New Engl J Med* 1988;319:1105-11
10. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. *Lancet* 1990;336:827-30
11. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. *Circulation* 1994;89:81-88
12. Telford AM, Wilson C. Trial of heparin vs atenolol in prevention of myocardial infarction in intermediate coronary syndrome. *Lancet* 1981;1(8232):1225-8
13. Théroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. *Circulation* 1993;88(part 1):2045-2048
14. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. *JAMA* 1996;276:811-815
15. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. *Lancet* 1996;347:561-68
16. Yusuf S, Flather M, Pogue J, Hunt D, Varigos J, Piegas L et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without ST elevation. *Lancet* 1998;352:507-14 (OASIS registry)

17. Stone SR, Maraganore JM. Hirudin interactions with thrombin. In: Berliner LJ ed. *Thrombin: Structure and Function*. New York, NY. Plenum Press; 1992:219-256
18. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. *Biochemistry* 1986;25(16):4622-8
19. Griessbach U, Sturzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. *Thromb Res* 1985;37(2):347-50
20. Hafner G, Fickenscher K, Friesen H-J, Rupprecht H-J, Konheiser U, Ehrental W et al. Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma. *Thromb Res* 1995;77(2):165-173
21. Berscheid G, Grötsch H, Neubauer H, Pünter J, Reindl J, Seipp P. Determination of rDNA hirudin and a human thrombin-hirudin complex in plasma samples: enzyme linked immunosorbent assays for hirudin and complex vs. chromogenic thrombin substrate assay. *Thromb Res* 1992;66:33-42
22. Fareed J, Walenga JM, Pifarre R, Hoppensteadt D, Koza M. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin. *Haemostasis* 1991;21 Suppl 1:64-72
23. Meyer BJ, Badimon JJ, Mailhac AA, Fernández-Ortiz A, Chesebro JH, Fuster V, Badimon L. Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. *Circulation* 1994;90:2432-38
24. Wysokinski W, McBane R, Chesebro JH, Owen WG. Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries. *Thromb Haemost* 1996;76(6):1108-13
25. Meyer B, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, Badimon L. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin. Comparison with heparin and aspirin. *Circulation* 1998;97:681-685
26. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. *Circulation* 1998;97:544-552
27. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. *Circulation* 1989;79:657-665
28. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ et al. Hirudin, heparin and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. *Circulation* 1990;82:1476-84
29. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. *Blood* 1991;77(5):1006-12
30. Lam JYT, Chesebro JH, Steele PM, Heras M, Webster MWI, Badimon L, Fuster V. Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. *Circulation* 1991;84:814-20
31. Just M, Tripier D, Seiffge D. Antithrombotic effects of recombinant hirudin in different animal models. *Haemostasis* 1991;21(Suppl 1):80-7
32. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (Ilepirudin) compared with heparin on death, myocardial infarction,

- refractory angina, and revascularisation procedures in patients with acute myocardial ischemia without ST elevation: a randomised trial. *Lancet* 1999;353:429-38 (**OASIS-2 study**)
33. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation. A pilot study. *Circulation* 1997;96:769-777 (**OASIS-1 study**)
 34. Anand SS, Yusuf S, Pogue J, Flather M for the OASIS Investigators. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results. *Circulation* 1998;98(1):1064-70 (**OASIS-1 study**)
 35. Rupprecht H-J, Terres W, Özbek C, Luz M, Jessel A, Hafner G et al. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina. *J Am Coll Cardiol* 1995;26:1637-42 (**PTCA study**)
 36. Hafner G, Rupprecht HJ, Luz M, Terres W, Schindel F, Friesen HJ et al. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris. *Eur Heart J* 1996;17:1207-15 (**PTCA study**)
 37. Fox KAA. r-Hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study. *Eur Heart J* 1995;16(Suppl D):28-32 (**APT-1 study**)
 38. Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J et al for the OASIS Pilot Study Investigators. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomised trial. Accepted for publication in *Eur Heart J* (**OASIS-1 study**)
 39. Agnelli G, Renga C, Weitz JI, Nenci GG, Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. *Blood* 1992;80(4):960-965
 40. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. *N Engl J Med* 1992;327:141-5
 41. Granger CB, Woodlief LH. Lack of rebound recurrence of reinfarction after discontinuation of antithrombin therapy: results from the GUSTO IIb Trial. *Circulation* 1996;94(8):I-431
 42. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). *Circulation* 1997;96:61-68
 43. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. *N Engl J Med* 1997;337:447-52
 44. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bernink PJLM, Salein D et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. *Circulation* 1999;100:1593-601
 45. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. *N Engl J Med* 1998;338:1498-505
 46. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet

- glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. *N Engl J Med* 1998;338:1488-97
47. FRAX.I.S Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S (FRAXiparine in Ischaemic Syndrome). *Eur Heart J* 1999;20:1553-1562
 48. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. *Circulation* 1994;90:1631-1637
 49. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. *N Engl J Med* 1996;335:775-82
 50. Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. *J Cardiovasc Pharmacol* 1993;22(3):364-72
 51. Longstaff C, Wong M-Y, Gaffney PJ. An international collaborative study to investigate standardisation of hirudin potency. *Thromb Haemost* 1993;69(5):430-435
 52. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. *Circulation* 1994;89:1557-1566
 53. Serruys PW, Herrman J-P, Simon R, Rutsch W, Bode C, Laarman G-J et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. *N Engl J Med* 1995;333:757-63
 54. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatid in patients with acute coronary syndromes. *N Engl J Med* 1998;339:436-43
 55. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. *Circulation* 1998;97:2386-2395
 56. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J et al. for the TIMI 11B and ESSENCE Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. *Circulation* 1999;100:1602-1608
 57. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA et al. Clinical outcomes of therapeutic agents that block platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. *Circulation* 1998;98:2829-2835
 58. Fleiss JL. *Statistical Methods for Rates and Proportions*. John Wiley & Sons, 2nd edition, 1981
 59. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. *Stat Med* 1991;10:1665-1677
 60. Cardiovascular and Renal Drugs Advisory Committee. 81st meeting, June 26, 1997. Transcript of meeting.
 61. Cardiovascular and Renal Drugs Advisory Committee. 82nd meeting, October 24, 1997. Transcript of meeting.
 62. Fleming TR. Evaluation of active control trials in AIDS. *JAIDS* 1990;3 (Suppl. 2):S82-S87

63. Bucher HC, Guyatt GH, Griffith LE and Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. *J Clin Epidemiol* 1997;50:683-691
64. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. *Circulation* 1987;76(1):142-154
65. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ et al. Stroke in patients with acute coronary syndromes. Incidence and outcomes in Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression using Integrilin Therapy (PURSUIT) Trial. *Circulation* 1999;99:2371-2377
66. Frye RL, Kronmal R, Schaff HV, Myers WO, Gersh BJ and the participants in the Coronary Artery Surgery Study. Stroke in coronary artery bypass graft surgery: an analysis of the CASS experience. *Int J Cardiol* 1992;36:213-221
67. McKhann GM, Goldsborough MA, Borowicz LM, Mellits ED, Brookmeyer R, Quaskey SA et al. Predictors of stroke risk in coronary artery bypass patients. *Ann Thorac Surg* 1997;63:516-521